UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


          Date of Report (Date of Earliest Event Reported): May 9, 2001


                         Shire Pharmaceuticals Group plc
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                England and Wales
- --------------------------------------------------------------------------------
                 (State or other jurisdiction of incorporation)


         0-29630                                      N/A
- ------------------------------     --------------------------------------------
(Commission File Number)                (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- --------------------------------------------------------------------------------
(Address of principal executive offices)                        (Zip code)

Registrant's telephone number, including area code            44 1256 894 000
                                                  ------------------------------



- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)







Item 7.  Financial Statements and Exhibits

     (c) Exhibits. The following exhibit is filed herewith:

          99.1 Presentation relating to first quarter results and BioChem
               Pharma, Inc. merger.




                                      -2-


                                    SIGNATURE


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:  May 11, 2001                 SHIRE PHARMACEUTICALS GROUP PLC



                                     By: /s/ Angus C. Russell
                                         ---------------------------------------
                                         Name:  Angus C. Russell
                                         Title: Group Finance Director







                                  EXHIBIT INDEX


Number   Description

          99.1 Presentation relating to first quarter results and BioChem
               Pharma, Inc. merger.